Market Research Report
Epiomic Epidemiology Series: Addison's Disease Forecast in 22 Major Markets 2018-2028
|Published by||Black Swan Analysis||Product code||354593|
|Published||Content info||70 Pages
Delivery time: 1-2 business days
|Epiomic Epidemiology Series: Addison's Disease Forecast in 22 Major Markets 2018-2028|
|Published: September 1, 2018||Content info: 70 Pages||
Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Addison's Disease in 22 Major Markets
Addison's disease (AD) is a chronic and rare endocrinal disorder, caused by destruction of the adrenal cortex which leads to the reduced production of glucocorticoids, mineralocorticoids and adrenal androgens. Chronic adrenal insufficiency and hypersecretion of ACTH is representative of the basic clinical signs and symptoms. AD can be part of the autoimmune polyglandular syndrome (PAS) (type 1 and 2), or it may present as an isolated disorder. PAS usually also affects other endocrine glands including the thyroid, pancreatic beta cells and stomach cells that allow absorption of vitamin B12 (producing pernicious anaemia).
This report provides the current prevalent population for AD across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Norway, Sweden, Iceland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, AD patients grouped by disease classification and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Ability to quantify patient populations in global AD market to target the development of future products, pricing strategies and launch plans.
Further insight into the prevalence of the subdivided types of AD and identification of patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Better understanding of the impact of specific co-morbid conditions on the prevalent population of AD patients.
Identification of AD patient sub-populations that require treatment.
Better understanding of the specific markets that have the largest number of AD patients.